Emphasizing statin safety in the hospitalized patient: A review

American Journal of Medicine

Volumn 125, Issue 9, 2012, Pages 845-853

  Leung, Alicia ^a   Schaefer, Eric W ^a   Tempelhof, Michael W ^a   Stone, Neil J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hepatotoxicity; Myotoxicity; Nephrotoxicity; Statin safety

Indexed keywords

AMIODARONE; AMLODIPINE; ATORVASTATIN; BOSENTAN; CLARITHROMYCIN; CREATININE; CYCLOSPORIN; DILTIAZEM; EFAVIRENZ; ERYTHROMYCIN; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHENYTOIN; PIOGLITAZONE; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYOPATHY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS;

ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG LABELING; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INPATIENTS; KIDNEY; LIVER; META-ANALYSIS AS TOPIC; MUSCLE, SKELETAL; ORGAN TRANSPLANTATION; PATIENT EDUCATION AS TOPIC; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865701053     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.02.022     Document Type: Review

References (58)

1. C. Baigent, A. Keech, P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
3. J.G. Robinson, B. Smith, N. Maheshwari, H. Schrott Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis J Am Coll Cardiol 46 2005 1855 1862
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
5. C. Baigent, L. Blackwell, J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
6. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
7. D.D. Waters, I. Ku Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation J Am Coll Cardiol 54 2009 1434 1437
8. J. Herrmann, A. Lerman, D. Baumgart Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction Circulation 106 2002 2180 2183
9. S.R. Mulukutla, O.C. Marroquin, C. Smith Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury Am J Cardiol 94 2004 1363 1366
10. J.A. Magovern, R.J. Moraca, S.H. Bailey Preoperative statin is associated with decreased operative mortality in high risk coronary artery bypass patients J Cardiothorac Surg 5 2010 8
11. G. Patti, V. Pasceri, G. Colonna Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial J Am Coll Cardiol 49 2007 1272 1278
12. D.E. Winchester, X. Wen, L. Xie, A.A. Bavry Evidence of pre-procedural statin therapy a meta-analysis of randomized trials J Am Coll Cardiol 56 2010 1099 1109
13. K. Rahimi, J. Emberson, P. McGale Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials BMJ 342 2011 d1250
14. C. Wanner, V. Krane, W. Marz Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics Kidney Blood Press Res 27 2004 259 266
15. B. Fellstrom, F. Zannad, R. Schmieder Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study Curr Control Trials Cardiovasc Med 6 2005 9
16. S. Ghio, L. Scelsi, R. Latini Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial Eur J Heart Fail 12 2010 1345 1353
17. J.J. McMurray, P. Dunselman, H. Wedel Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure) J Am Coll Cardiol 56 2010 1196 1204
18. P.M. Kearney, L. Blackwell, R. Collins Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
19. K. Matsushita, M. van der Velde, B.C. Astor Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Lancet 375 2010 2073 2081
20. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
21. K.K. Stevens, A.G. Jardine SHARP: a stab in the right direction in chronic kidney disease Lancet 377 2011 2153 2154
22. J.A. Kobashigawa, J.D. Moriguchi, H. Laks Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients J Heart Lung Transplant 24 2005 1736 1740
23. C.D. Malvestutto, J.A. Aberg Coronary heart disease in people infected with HIV Cleve Clin J Med 77 2010 547 556
24. R.D. Moore, J.G. Bartlett, J.E. Gallant Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients PLoS One 6 2011 e21843
25. Pitavastatin (Livalo)-the seventh statin Med Lett Drugs Ther 52 2010 57 58
26. C.D. Furberg, B. Pitt Withdrawal of cerivastatin from the world market Curr Control Trials Cardiovasc Med 2 2001 205 207
27. S. Bellosta, R. Paoletti, A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 23 Suppl 1 2004 III50 III57
28. Y. Saito Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals Vasc Health Risk Manag 5 2009 921 936
29. P.D. Thompson, P. Clarkson, R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
30. B. Ricaurte, A. Guirguis, H.C. Taylor, D. Zabriskie Simvastatin- amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity Ann Pharmacother 40 2006 753 757
31. L. Becquemont, M. Neuvonen, C. Verstuyft Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics Clin Pharmacol Ther 81 2007 679 684
32. B. Akman, M. Uyar, B. Afsar, S. Sezer, F.N. Ozdemir, M. Haberal Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids Transplant Proc 39 2007 135 137
33. S.R. Penzak, S.K. Chuck, G.V. Stajich Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection Pharmacotherapy 20 2000 1066 1071
34. C.J. Fichtenbaum Metabolic abnormalities associated with HIV infection and antiretroviral therapy Curr Infect Dis Rep 11 2009 84 92
35. L. Calza, R. Manfredi, V. Colangeli, D. Pocaterra, M. Pavoni, F. Chiodo Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors Curr HIV Res 6 2008 572 578
36. E. Aslangul, L. Assoumou, R. Bittar Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial AIDS 24 2010 77 83
37. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol Ther 84 1999 413 428
38. H.N. Ginsberg, M.B. Elam, L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
39. P.D. Thompson, P.M. Clarkson, R.S. Rosenson An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
40. M. Carter, J.H. O'Keefe Is red yeast rice a suitable alternative for statins? Mayo Clin Proc 83 2008 1294 author reply 1294-1296
41. E. Link, S. Parish, J. Armitage SLCO1B1 variants and statin-induced myopathy-a genomewide study N Engl J Med 359 2008 789 799
42. Pharmacokinetics of statin drugs http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2011/ucm258338.htm Accessed December 18, 2011
43. S.M. Grundy The issue of statin safety: where do we stand? Circulation 111 2005 3016 3019
44. B.B. Murinson, N.J. Maragakis, T.A. Jacobson Fluvastatin, rhabdomyolysis, and myotoxicity Mayo Clin Proc 83 2008 1296 author reply 1297
45. E. Bruckert, G. Hayem, S. Dejager, C. Yau, B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
46. M.P. McGowan There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients Circulation 110 2004 2333 2335
47. E.C. Charles, K.L. Olson, B.G. Sandhoff, D.L. McClure, J.A. Merenich Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization Am J Med 118 2005 618 624
48. FDA Expands Advice on Statin Risks http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm293330.htm Accessed April 4, 2012
49. R.M. Calderon, L.X. Cubeddu, R.B. Goldberg, E.R. Schiff Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma Mayo Clin Proc 85 2010 349 356
50. D.E. Cohen, F.A. Anania, N. Chalasani An assessment of statin safety by hepatologists Am J Cardiol 97 2006 77C 81C
51. P.B. Watkins, N. Kaplowitz, J.T. Slattery Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial JAMA 296 2006 87 93
52. B.L. Kasiske, C. Wanner, W.C. O'Neill An assessment of statin safety by nephrologists Am J Cardiol 97 2006 82C 85C
53. N. Sattar, D. Preiss, H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
54. D. Preiss, S.R. Seshasai, P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
55. G.C. Fonarow, C.M. Ballantyne In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now Circulation 103 2001 2768 2770
56. G.C. Fonarow, A. Gawlinski, S. Moughrabi, J.H. Tillisch Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) Am J Cardiol 87 2001 819 822
57. M. McCarthy US heart-guidelines strategy makes promising start Lancet 358 2001 1618
58. G.C. Fonarow In-hospital initiation of statins: taking advantage of the 'teachable moment' Cleve Clin J Med 70 2003 502 504-506